MARKET

APVO

APVO

Aptevo Therapeutics Inc
NASDAQ
1.910
+0.020
+1.06%
After Hours: 1.910 0 0.01% 19:45 09/28 EDT
OPEN
1.860
PREV CLOSE
1.890
HIGH
1.980
LOW
1.860
VOLUME
47.83K
TURNOVER
--
52 WEEK HIGH
35.64
52 WEEK LOW
1.370
MARKET CAP
3.46M
P/E (TTM)
-0.0329
1D
5D
1M
3M
1Y
5Y
1D
Aptevo Advances Next-Generation Trispecific Immuno-Oncology Programs
TipRanks · 4d ago
Aptevo Therapeutics advances trispecific candidate toward clinical development
TipRanks · 4d ago
Aptevo Expects To Enter Investigational New Drug-Enabling Studies For Its Lead Candidate APVO451 In H1 2027
Benzinga · 4d ago
Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development
Barchart · 4d ago
Aptevo Shareholders Approve Equity Issuance, Reject Charter Changes
TipRanks · 5d ago
Weekly Report: what happened at APVO last week (0914-0918)?
Weekly Report · 09/21 09:12
Weekly Report: what happened at APVO last week (0907-0911)?
Weekly Report · 09/14 09:13
Weekly Report: what happened at APVO last week (0831-0904)?
Weekly Report · 09/07 09:12
More
About APVO
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. The Company has two clinical candidates: Mipletamig and ALG.APV-527. Mipletamig is being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The Company has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates are created from two proprietary platforms, ADAPTIR and ADAPTIR-FLEX.

Webull offers Aptevo Therapeutics Inc stock information, including NASDAQ: APVO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APVO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APVO stock methods without spending real money on the virtual paper trading platform.